About
Profile
STERIS is a leading provider of infection prevention and procedural products and services, focused primarily on the critical markets of healthcare, pharmaceutical and research and medical devices. Our MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AN
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
STE
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Steris Q3 2024 Earnings Preview
- Steris declares $0.52 dividend
- Goldman Sachs 2024 stock strategy - high quality
- Steris beats Q2 top and bottom line estimates; reaffirms FY23 outlook
- Steris Q2 2024 Earnings Preview
- Steris declares $0.52 dividend
- Quant stock news sentiment measure keeps improving - BofA
- JPMorgan says time to buy MedTech based on past
- Steris Non-GAAP EPS of $2.00 beats by $0.14, revenue of $1.28B beats by $70M
- Steris Q1 2024 Earnings Preview
- Steris raises dividend by 11% to $0.52
- Becton, Dickinson selling surgical instrumentation unit to STERIS for $540M
- Morgan Stanley's top medtech picks are Medtronic, Alphatec, Becton Dickinson
- Steris Non-GAAP EPS of $2.30 beats by $0.15, revenue of $1.38B beats by $110M
- Steris Q4 2023 Earnings Preview
- Steris declares $0.47 dividend, announces $500M buyback
- Steris lower as Piper Sandler downgrades on the outlook
- EPA proposes new measures to cut emissions of carcinogenic gas ethylene oxide
- Steris falls 10% on Q3 revenue, profit miss, 2023 profit guidance lowered
- Steris Non-GAAP EPS of $2.02 misses by $0.17, revenue of $1.22B misses by $50M